Expiration date: 12/2026
Dosage form
pills for resorption.
Composition (for 1 tablet)
Active substances:
Moskomarhitectura antibodies to protein S-100 affine purified – 0.006 g*
Antibodies to cannabinoid receptor type I affine purified – 0.006 g*
Excipients: lactose monohydrate, cellulose microcrystalline, magnesium stearate.
*applied to the lactose in the form of a mixture of three active water-alcohol dilutions of the substance diluted, respectively, in the 10012, 10030, 100200 times.
Description
Pills valium forms, with valium and chamfer white to almost white. On the flat side with the mark affixed MATERIA MEDICA, on the other flat side affixed Brisanten.
Pharmacotherapeutic group
Nicotine addiction treatment, alcoholism treatment.
Pharmacological properties
Pharmacodynamics
Combined preparation:
Moskomarhitectura antibodies to protein S-100 have antioxidant, antihypoxic, neuroprotective, anxiolytic, antidepressant activity. Modify the functional activity of protein S-100, those in the brain pairing information and metabolic processes. Possess membranotropic effect, causing a decrease in the amplitude and suppression of the generation of the action potential, modulate synaptic transmission in the limbic structures of the brain, the hippocampus, the reticular formation contribute to the increase of inhibitory effect of GABA in the CNS. Exhibit the properties of an agonist of Sigma 1 receptor in vitro.
Inhibit the processes of lipid peroxidation.
Antibodies to cannabinoid receptor type I modulate the functional activity of the cannabinoid receptor type 1, affect the concentration of intracellular camp. Regulate endocannabinoid system in the CNS (mainly in the neurons of the mesolimbic system) and peripheral tissues, normalizes energy balance (metabolism of glucose and lipids).
Experimentally, on models of self-stimulation of lateral hypothalamus antiaddictive shown a synergistic effect when used together, the two components in the complex preparation of Bizantin.
Brisanten modulates a system of positive emotional reinforcement, thereby reducing the severity of attraction to psychoactive substances alcoholism and nicotinism, normalizes the balance of neurotransmitters in the CNS.
Brisanten also exhibits neuroprotective activity, enhances brain resistance to toxic effects, improves integrative activity, helps to eliminate cognitive impairment, increases mental performance, normalizes somatic and vegetative manifestations in withdrawal States.
The drug eliminates affective (irritability, depressed mood, inner discomfort), and ideational (thoughts about nicotine, or alcohol) and asthenovegetative violations (expressed General weakness, decreased performance, appetite, sweating, tachycardia, etc.). Has no sedative, muscle relaxant action, not addictive, drug dependence, has no narcotic potential.
Pharmacokinetics
The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high performance liquid chromatography, gas chromatography-mass spectrometry) does not allow to assess the content of ultra-low doses of antibodies in biological fluids, organs and tissues, that makes technically impossible the study of the pharmacokinetics of the drug of Bizantin.
Indications for use
The drug is used to reduce the craving for alcohol and nicotine as in the first days of the rejection of their admission (period of abstinence) and impulsive manifested the desire of their use.
Contraindications
Increased individual sensitivity to product components. Brisanten not recommended for use in children under the age of 18 years due to insufficient data on efficacy and safety for this age.
Pregnancy and lactation
The safety of the Brisanten during pregnancy and lactation has not been studied. If necessary, the drug should be taken into account, the ratio risk/benefit.
Method of application and doses
Inside. At one time - 1 tablet (hold in mouth until dissolved). Apply 1 tablet 2-3 times a day outside meals. With increasing desire for alcohol and/or nicotine may increase the frequency of taking up to 5-6 times a day.
Side effects
Possible reactions of individual hypersensitivity to the drug components.
Overdose
In case of accidental overdose dyspeptic symptoms caused by members of the drug fillers.
Interaction with other drugs
No incompatibilities with other drugs to date is not registered.
Special instructions
The preparation includes lactose, and therefore it is not recommended to appoint patients with congenital galactosemia, syndrome of malabsorption of glucose or galactose, or congenital lactase deficiency.
Brisanten has no effect on the ability to drive vehicles and other potentially dangerous machinery.
Release form
Pills for resorption. Of 20 tablets in blister made of polyvinylchloride film and aluminum foil.
1, 2 or 5 contour cell packages along with instructions for medical use are placed in a cardboard pack.
Storage conditions
In protected from light place, at temperature not above 25 °C.
Keep out of reach of children.
Shelf life
3 years.
Do not use after expiration date.
